Anaplastic Thyroid Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Anaplastic Thyroid Cancer – Pipeline Review, H2 2016’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer

The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daiichi Sankyo Company, Limited

Genelux Corporation

Immune Pharmaceuticals Inc.

Millennium Pharmaceuticals Inc

Novartis AG

Pfizer Inc.

Plexxikon Inc.

Trophogen, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anaplastic Thyroid Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Anaplastic Thyroid Cancer - Overview 8

Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9

Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10

Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11

Anaplastic Thyroid Cancer - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Anaplastic Thyroid Cancer - Products under Development by Companies 14

Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15

Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16

Daiichi Sankyo Company, Limited 16

Genelux Corporation 17

Immune Pharmaceuticals Inc. 18

Millennium Pharmaceuticals Inc 19

Novartis AG 20

Pfizer Inc. 21

Plexxikon Inc. 22

Trophogen, Inc. 23

Anaplastic Thyroid Cancer - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

ceritinib - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CLM-3 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

crizotinib - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

crolibulin - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

efatutazone - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

GLONC-2 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GLV-1h153 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

pexidartinib - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

PLX-8394 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

sapanisertib - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

utomilumab - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Anaplastic Thyroid Cancer - Dormant Projects 70

Anaplastic Thyroid Cancer - Product Development Milestones 71

Featured News & Press Releases 71

Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds 71

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

List of Tables

Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016 8

Number of Products under Development for Anaplastic Thyroid Cancer – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Anaplastic Thyroid Cancer – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 16

Anaplastic Thyroid Cancer – Pipeline by Genelux Corporation, H2 2016 17

Anaplastic Thyroid Cancer – Pipeline by Immune Pharmaceuticals Inc., H2 2016 18

Anaplastic Thyroid Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 19

Anaplastic Thyroid Cancer – Pipeline by Novartis AG, H2 2016 20

Anaplastic Thyroid Cancer – Pipeline by Pfizer Inc., H2 2016 21

Anaplastic Thyroid Cancer – Pipeline by Plexxikon Inc., H2 2016 22

Anaplastic Thyroid Cancer – Pipeline by Trophogen, Inc., H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Assessment by Combination Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Anaplastic Thyroid Cancer – Dormant Projects, H2 2016 70

List of Figures

List of Figures

Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016 8

Number of Products under Development for Anaplastic Thyroid Cancer – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports